Effectiveness of DTaP Against Pertussis in≤2-Year-Old Children—Linyi Prefecture,Shandong Province,China,2017–2019  

作　　者：Pinpin Zhu Dan Wu Yan Wang Xiaoxue Liu Lance ERodewald Yixing Li Hui Zheng Lei Cao Yifan Song Li Song Xiaodong Zhao Jianyi Yao Fuzhen Wang Mingshuang Li Qian Zhang Tingting Yan Zundong Yin 

机构地区：[1]National Immunization Program,Chinese Center for Disease Control and Prevention,Beijing,China [2]Linyi Center for Disease Control and Prevention,Linyi City,Shandong Province,China [3]Jinan Center for Disease Control and Prevention,Jinan City,Shandong Province,China [4]Health Communication Center,Chinese Center for Disease Control and Prevention,Beijing,China

出　　处：《China CDC weekly》2023年第17期374-378,I0006-I0009,共9页中国疾病预防控制中心周报（英文）

基　　金：Supported by the Joint Foundation of Beijing Natural Science Foundation and Haidian Original Innovation(L202037);as well as the Chinese Center for Disease Control and Prevention's Operation of Public Health Emergency Response Mechanism(131031001000200001).

摘　　要：Summary What is already known about this topic?Vaccine effectiveness(VE)is positively correlated with the number of administered co-purified diphtheria,tetanus,and acellular pertussis vaccine(DTaP)doses.A matched case-control study conducted in Zhongshan City revealed that the co-purified DTaP VE against pertussis-related illnesses in children aged 4–11 months was 42%for one dose,88%for two doses,and 95%for three doses,respectively.What is added by this report?The results of this study contribute to the current body of research.We found that the VE of co-purified DTaP against pertussis-related illness and hospitalization increased substantially,ranging from 24%–26%after one dose to 86%–87%after four doses.

关 键 词：doses DTAP VACCINE 

分 类 号：R186[医药卫生—流行病学]